Frank A. Holler is Director at Xenon Pharmaceuticals Inc. (XENE). They have made 6 open-market trades across 1 company since 2016, most recently 2021-05-27.
CIK 0000938801
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 6 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| XENE | 143,653 | $4.8M |
Shares reported on the most recent Form 4, priced at the 2021-06-01 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| XENE | SELL | 2021-05-27 | 2021-06-01 | $18.68 | $365K | -1.1% | -1.6% | -10.1% |
| XENE | SELL | 2019-09-19 | 2019-09-20 | $9.32 | $119K | -3.9% | -4.1% | +42.2% |
| XENE | SELL | 2019-09-17 | 2019-09-18 | $9.30 | $88K | -2.4% | -4.7% | +41.1% |
| XENE | SELL | 2016-12-15 | 2016-12-19 | $7.85 | $236K | -5.5% | +3.1% | +1.2% |
| XENE | SELL | 2016-08-19 | 2016-08-23 | $7.65 | $183K | +1.0% | +1.0% | +2.3% |
| XENE | SELL | 2016-08-16 | 2016-08-18 | $7.93 | $274K | +3.3% | +3.4% | +1.0% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.